SecBot SecBot

MRKR

Marker Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001094038 Biotech & Drug Discovery
$0.8300 −0.04 (−4.60%)
Nov 16 4:00 PM ET · prev $0.8700
Market cap
$15.0M
Nano cap
Median target
$8.00
+864% · range $5.60–10.00
1 year
−12.6%
from $0.9500 · Nov 17
30 days
−30.8%
from $1.20
52-week range
$0.8300–2.19
at the low
Avg volume 20D
123.6K
shares / day
Short interest
176.1K
≈1.1% of shares · +61.4%
Days to cover
1.0
at average volume
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
3
analyzed by SecBot
SecBot read BULLISH 2 reports · 90 days
Balance 0 bearish · 2 bullish oldest → newest, height = score
Avg score ·High conf. 2/2

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InstitutionsMIXED

    Q3 2026: 1 added (0 new), 2 trimmed or exited.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.185 → −$0.140 over 90 days. 1 up, 0 down in 30 days.

  • Short sellersBUILDING

    Short interest +61.4% to 176.1K shares. 1.0 days to cover, ≈1.1% of shares.

  • TrendDOWNTREND

    21% below its 50-day average. New closing low $0.8300 on Nov 16.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
JANE STREET GROUP, LLCTRIM12,250$13.1K
UBS Group AGADD12,183$13.0K
RENAISSANCE TECHNOLOGIES LLCADD249,423$366.7K
NORTHERN TRUST CORPADD34,629$50.9K
JANE STREET GROUP, LLCTRIM16,832$24.7K
UBS Group AGTRIM8,150$12.0K
RENAISSANCE TECHNOLOGIES LLCADD175,294$227.9K
UBS Group AGNEAR_EXIT32,369$42.1K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action Dec 2025
12-month targets · 3 analysts

Price is below the lowest target. Median implies +864%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Dec 8, 2025HC Wainwright & Co.
INITIATE
INITIATEBuy
Apr 1, 2025WBB Securities
REITERATE
REITERATEStrong Buy
Mar 5, 2025Canaccord Genuity
INITIATE
INITIATEBuy
Apr 30, 2024Ladenburg Thalmann
INITIATE
INITIATEBuy

Earnings setup

Estimates
−$0.14
EPS estimate, this quarter
+24%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.14-$0.16–-$0.12+0.0%$2.1M
Next Q-$0.17-$0.22–-$0.12+0.0%$715.3K
Current FY-$0.56-$0.63–-$0.50+0.0%$4.2M
Next FY-$0.53-$0.89–-$0.17+0.0%$20.2M
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
1 drug tracked · Drug pipeline →
Recent

SecBot reports

3 filings · 2 press releases · 1 bullish · 0 bearish · 1 mixed · 1 neutral
All MRKR filing & press-release reports (5)